NCT01714804CompletedNot Applicable
Efficacy and Safety of Integra Accell Evo3 Demineralized Bone Matrix in Instrumented Lumbar Spine Fusion
Conditions
Interventions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- SeaSpine, Inc.
- Enrollment
- 30
- Locations
- 1
- Primary Endpoint
- Number of Levels With Posterolateral Fusion
Study Overview
Brief Summary
The objective of this study is to prospectively evaluate the performance of Integra Accell Evo3 Demineralized Bone Matrix as an adjunct for instrumented lumbar spine fusion with a retrospective comparison to a historical patient cohort.
Detailed Description
The objective of this study is to prospectively evaluate the performance of Integra Accell Evo3 Demineralized Bone Matrix as an adjunct for instrumented lumbar spine fusion in comparison to a retrospective cohort of Infuse subjects. Infuse subjects were not enrolled in the current study.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Are 18 (eighteen) years of age or older at the time of surgery.
- •Require spinal fusion using TLIF, PLF or PLIF, with the use of an interbody spacer, at 1 to 3 levels between L3-S
- •Willing and able to return for the scheduled follow-up visits, follow post-operative instructions and undergo the required radiographic exams (A/P, Lateral Neutral and Lateral Flexion/Extension X-rays) for up to 3 time points between 6 months and 24 months post-surgery (6±2 months, 12±3 months and 24±4 months post-surgery), including one CT-scan at 12±3 months.
- •Unresponsive to conservative care over a period of at least 6 months or has signs and/or symptoms that mandate urgent surgical intervention.
Exclusion Criteria
- •Are long term users of medications (i.e. steroids greater than 2-weeks) that are known to inhibit fusion or bone metabolism at any time within 6 months prior to surgery. Exceptions are inhaled steroids for asthma treatment (i.e. patients on inhaled steroids are allowed), or epidural steroid injections.
- •Are taking immunosuppressive agents (Cancer chemotherapy, treatment with Disease Modifying Anti-rheumatic drugs (DMARDs) or any similar immunomodulating drugs) or are treated with Growth Factors or Insulin at any time within 6 months prior to surgery.
- •Are being treated with radiotherapy.
- •Are having medical conditions, known to impact bone metabolism, such as Paget's disease, osteoporosis.
- •Are smokers and/or nicotine/tobacco users.
- •Are pregnant, lactating or women wishing to become pregnant.
- •Are a prisoner.
- •Are currently participating in an investigational drug or another device study that has not completed the primary endpoint or that clinically interferes with the study endpoints.
- •Prior spine surgery at the index level except posterior decompressive surgery where the posterior elements are preserved e.g. facet saving techniques such as discectomy, laminotomy, and intradiscal procedures.
- •Use of any other bone graft or bone graft substitute in addition to or in place of Accell Evo3® with the exception of local autograft and/or cancellous bone chips.
- •Use of routine prophylactic NSAIDS for 3 months post-operatively, but low dose concomitant pain medications e.g. aspirin should be continued and recorded on the Concomitant Pain Medications case report form (CRF).
Arms & Interventions
Prospective
Experimental
Accell Evo3
Intervention: Accell Evo3 Prospective Use (Device)
Outcomes
Primary Outcomes
Number of Levels With Posterolateral Fusion
Time Frame: 12 months
Assessment of fusion in the posterolateral space was performed using by X-ray and/or CT. Assessment was performed by the operating surgeon blinded towards patient. Each spinal level was graded separately
Secondary Outcomes
- Oswestry Disability Index (ODI), Visual Analog Scale (VAS) for Pain in the Back (VAS-back) and in the Leg (VAS-leg)(12 months)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Not Applicable
Efficacy and Safety of Accell Evo3 Demineralized Bone Matrix (DBM) in Instrumented Posterolateral Lumbar Spine FusionStenosisDegenerative ChangesSpondylosisNCT01430299SeaSpine, Inc.43
Completed
Not Applicable
Modulus in XLIF StudyDegenerative SpondylolisthesisDegenerative Disc DiseaseDegenerative ScoliosisNCT04418817NuVasive36
Completed
Phase 3
MR Guided Focused Ultrasound Treatment of Uterine Fibroids With Enhanced SonicationUterine FibroidsUterine LeiomyomaNCT00365989InSightec50
Completed
Not Applicable
Safety and Performance of INVICTA Ventricular DF4 LEADS With Active Fixation-(APOLLO)Ventricular ArrythmiaLeadICDHeart FailureNCT04590144MicroPort CRM446
Unknown
Not Applicable
Performance and Safety Evaluation of the S360 Medical Device Software.Binocular Eye Movement DisorderBinocular Vision DisorderOcular Motion DisorderNCT05522595Sierra Neurovision200